Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2013-07-17 Regulatory Filings
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Commencement of phase II lupus trial 2 pages 331.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX media announcement dated 18 July 2013 from Invion Limited. It announces the commencement of a Phase II clinical trial for a drug candidate INV103 targeting lupus. The content focuses on the clinical trial initiation, FDA IND acceptance, trial protocol, clinical sites, and company background. There are no financial statements, earnings data, or detailed financial analysis. The document is a public announcement of a clinical trial start, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention a report being attached or published. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a clinical trial commencement and FDA acceptance, which does not fit other specific categories like earnings release, capital update, or management information.
2013-07-17 English
Notice of General Meeting/Proxy Form 13 pages 527.8KB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of General Meeting for Invion Limited, detailing resolutions to be voted on at the meeting. The resolutions primarily concern the approval of share placements and issuance of options to related parties, referencing ASX Listing Rules and the Corporations Act. The document includes explanatory memoranda and voting exclusion statements. It is a formal notice sent to shareholders to inform them of the meeting agenda and request their votes on specific corporate actions. There is no financial data, earnings information, or management discussion of results. The document is not a report but a meeting notice with resolutions to be voted on, which fits the category of Proxy Solicitation & Information Statement (PSI).
2013-07-11 English
Invion announces $2M placement 2 pages 272.9KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement dated 11 June 2013 from Invion Limited regarding a $2 million private placement of shares to sophisticated and professional investors. It details the number of shares issued, the issue price, the use of funds, and the participation of directors subject to shareholder approval. The content focuses on fundraising and capital raising activities, including the structure of the placement and related shareholder approvals. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is clearly an update on capital raising activity rather than a full financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 4611 characters, which is consistent with a detailed announcement but not a full report.
2013-06-10 English
Section 708A Notice 1 page 297.2KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 11 June 2013 regarding the issue of shares by Invion Limited without disclosure under section 708A of the Corporations Act 2001. It references the issuance of shares and compliance with disclosure provisions but does not contain financial statements or detailed financial data. The document is short (1214 characters) and serves as a formal notice of a share issue without disclosure, which aligns with announcements about capital changes. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2013-06-10 English
Appendix 3B 12 pages 607.9KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcing new issues of securities, applications for quotation of additional securities, and related agreements. It details the number and class of securities issued, issue price, purpose of the issue, and compliance with ASX listing rules. The document does not contain financial statements or detailed financial performance data but is focused on capital raising and securities issuance information. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes.
2013-06-10 English
Trading Halt 2 pages 292.9KB
Capital/Financing Update Classification · 95% confidence The document is a market release dated 6 June 2013 from Invion Limited, announcing a trading halt of its securities pending the release of an announcement regarding a proposed capital raising. The text references Listing Rule 17.1 and explicitly states the halt is requested due to a forthcoming announcement about capital raising. There are no financial statements, detailed financial data, or report contents included. The document is short (1639 characters) and serves as a notification of a trading halt rather than a report or detailed update. This fits the category of a Capital/Financing Update (CAP), as it relates to company fundraising activities and capital structure changes.
2013-06-05 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.